Target Markets

Our lead programs are addressing multi-billion dollar healthcare indications

Clostridioides difficile Infections (CDI)

C. difficile bacteria are found in the environment, including the human gut and in faeces.
Read More

Post-surgical Infections

Destiny Pharma’s lead product exeporfinium chloride (XF-73) focuses on addressing the medical and financial cost of infections.
Read More


COVID-19 is a new respiratory virus that has caused a major global pandemic. There is an urgent need for new treatments for COVID-19 and related viral infections.
Read More

Anti-Microbial Resistance

Infections caused by Anti-Microbial Resistant (AMR) strains of bacteria continue to rise at an alarming rate.
Read More